Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

Gastroenterology

Volumn 149, Issue 1, 2015, Pages 201-210

  Beatty, Gregory L ^a   Winograd, Rafael ^a   Evans, Rebecca A ^a   Long, Kristen B ^a   Luque, Santiago L ^a   Lee, Jae W ^a   Clendenin, Cynthia ^a   Gladney, Whitney L ^a   Knoblock, Dawson M ^a   Guirnalda, Patrick D ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lymphocyte; Pancreatic Cancer Treatment; Tolerance; Tumor Microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; FGK 45; GEMCITABINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CD40 ANTIGEN; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD40; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MACROPHAGES; MICE; PANCREATIC NEOPLASMS;

EID: 84931434511     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.04.010     Document Type: Article

References (38)

1. G.L. Beatty, E.G. Chiorean, and M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
2. D.T. Le, E. Lutz, and J.N. Uram Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer J Immunother 36 2013 382 389
3. R.E. Royal, C. Levy, and K. Turner Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J Immunother 33 2010 828 833
4. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
5. C. Feig, J.O. Jones, M. Kraman, and R.J. Wells Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc Natl Acad Sci U S A 110 2013 20212 20217
6. E. Tran, S. Turcotte, and A. Gros Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer Science 344 2014 641 645
7. P.F. Robbins, Y.C. Lu, and M. El-Gamil Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat Med 19 2013 747 752
8. N. van Rooij, M.M. van Buuren, and D. Philips Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J Clin Oncol 31 2013 e439 e442
9. B. Vogelstein, N. Papadopoulos, and V.E. Velculescu Cancer genome landscapes Science 339 2013 1546 1558
10. I.M. Stromnes, J.S. Brockenbrough, and K. Izeradjene Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity Gut 63 2014 1769 1781
11. L.J. Bayne, G.L. Beatty, and N. Jhala Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer Cancer Cell 21 2012 822 835
12. S.R. Hingorani, L. Wang, and A.S. Multani Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Cancer Cell 7 2005 469 483
13. A.K. Nowak, B.W. Robinson, and R.A. Lake Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 2003 4490 4496
14. B.P. Keenan, Y. Saenger, and M.I. Kafrouni A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice Gastroenterology 146 2014 1784 1794.e6
15. C.E. Clark, G.L. Beatty, and R.H. Vonderheide Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer Cancer Lett 279 2009 1 7
16. Y. Zhang, W. Yan, and E. Mathew CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice Cancer Immunol Res 2 2014 423 435
17. L.M. Coussens, L. Zitvogel, and A.K. Palucka Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339 2013 286 291
18. Y. Pylayeva-Gupta, K.E. Lee, and C.H. Hajdu Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Cancer Cell 21 2012 836 847
19. A.L. Mellor, and D.H. Munn Creating immune privilege: active local suppression that benefits friends, but protects foes Nat Rev Immunol 8 2008 74 80
20. M. De Palma, and C.E. Lewis Macrophage regulation of tumor responses to anticancer therapies Cancer Cell 23 2013 277 286
21. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 2009 162 174
22. D.G. DeNardo, D.J. Brennan, and E. Rexhepaj Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy Cancer Discov 1 2011 54 67
23. J.B. Mitchem, D.J. Brennan, and B.L. Knolhoff Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses Cancer Res 73 2013 1128 1141
24. A.M. Lesokhin, T.M. Hohl, and S. Kitano Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment Cancer Res 72 2012 876 886
25. S.L. Highfill, Y. Cui, and A.J. Giles Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy Sci Transl Med 6 2014 237ra67
26. G.P. Dunn, L.J. Old, and R.D. Schreiber The three Es of cancer immunoediting Annu Rev Immunol 22 2004 329 360
27. J.Y. Niederkorn See no evil, hear no evil, do no evil: the lessons of immune privilege Nat Immunol 7 2006 354 359
28. R.A. Franklin, W. Liao, and A. Sarkar The cellular and molecular origin of tumor-associated macrophages Science 344 2014 921 925
29. Y. Zheng, C.N. Manzotti, and M. Liu CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells J Immunol 172 2004 2778 2784
30. L. Zitvogel, L. Apetoh, and F. Ghiringhelli Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 2008 59 73
31. J.P. Ridge, F. Di Rosa, and P. Matzinger A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell Nature 393 1998 474 478
32. S.P. Schoenberger, R.E. Toes, and E.I. van der Voort T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 1998 480 483
33. Y. Zhang, H.J. Cao, and B. Graf CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts J Immunol 160 1998 1053 1057
34. L. Diehl, A.T. den Boer, and S.P. Schoenberger CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 1999 774 779
35. R.R. French, H.T. Chan, and A.L. Tutt CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help Nat Med 5 1999 548 553
36. E.M. Sotomayor, I. Borrello, and E. Tubb Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 Nat Med 5 1999 780 787
37. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
38. C.E. Clark, S.R. Hingorani, and R. Mick Dynamics of the immune reaction to pancreatic cancer from inception to invasion Cancer Res 67 2007 9518 9527